The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry

Recruiting now

Conditions studied: Kidney Neoplasm

In brief

Retrospective studies indicate that active surveillance for clinically localized, small renal masses (cT1a, \<=4cm) is safe. It is our hypothesis that active surveillance is safe and efficacious when compared prospectively to patients undergoing immediate intervention for their small renal mass.

Key facts

Study ID

NCT02346435

Run by

Abramson Cancer Center at Penn Medicine

People needed

600

Starts

2009-01-01

Expected to finish

2028-01-01

Last updated by the study team

2026-03-05

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Must have a solid, enhancing renal mass ≤4cm at its greatest dimension found on incidental scanning in the last 6 months.
• Age ≥ 18 and able to read, understand and sign informed consent.
• Must be willing to adhere to the treatment algorithm and time constraints therein.

You may not qualify if…

• Cannot have suspicion of metastases to the kidney if any other malignancy diagnosed within two years of study entry.

Where it is running

• Johns Hopkins Hospital — Baltimore, Maryland, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.